Limited-stage small-cell lung cancer: The current status of combined-modality therapy

Journal of Clinical Oncology

Volumn 25, Issue 26, 2007, Pages 4137-4145

  Socinski, Mark A ^a   Bogart, Jeffrey A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; MITUMUMAB; PACLITAXEL; TAMOXIFEN; THALIDOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

AREA UNDER THE CURVE; BONE SCINTISCANNING; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGITIS; GERIATRIC PATIENT; HUMAN; LUNG SMALL CELL CANCER; LUNG TOXICITY; MAXIMUM TOLERATED DOSE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKULL IRRADIATION; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ANIMAL; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; SMALL CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING;

EID: 34748903521     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.5303     Document Type: Review

References (91)

1. American Cancer Society: Cancer Facts and Figures 2006. http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2006.asp
2. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539-4544, 2006
3. Komaki R: Combined treatment for limited small cell lung cancer. Semin Oncol 30:56-70, 2003 (suppl 9)
4. Lee CB, Morris DE, Fried DB, et al: Current and evolving treatment options for limited stage small cell lung cancer. Curr Opin Oncol 18:162-172, 2006
5. Shepherd FA, Ginsberg RJ, Haddad R, et al: Importance of clinical staging in limited small-cell lung cancer: A valuable system to separate prognostic subgroups - The University of Toronto Lung Oncology Group. J Clin Oncol 11:1592-1597, 1993
6. Gaspar LE, Gay EG, Crawford J, et al: Limited-stage small-cell lung cancer (stages I-III): Observations from the National Cancer Data Base. Clin Lung Cancer 6:355-360, 2005
7. Ettinger DS, Aisner J: Changing face of small-cell lung cancer: Real and artifact. J Clin Oncol 24:4526-4527, 2006
8. Janne PA, Freidlin B, Saxman S, et al: Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer 95:1528-1538, 2002
9. Laskin JJ, Erridge SC, Coldman AJ, et al: Population-based outcomes for small cell lung cancer: Impact of standard management policies in British Columbia. Lung Cancer 43:7-16, 2004
10. Yau T, Ashley S, Popat S, et al: Time and chemotherapy treatment trends in the treatment of elderly patients (age >/=70 years) with small cell lung cancer. Br J Cancer 94:18-21, 2006
11. Lebitasy MP, Hedelin G, Purohit A, et al: Progress in the management and outcome of small-cell lung cancer in a French region from 1981 to 1994. Br J Cancer 85:808-815, 2001
12. Brink I, Schumacher T, Mix M, et al: Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 31:1614-1620, 2004
13. Blanco C, Lopez-Picazo J, Boan J, et al: Initial staging of small-cell lung cancer (SCLC) patients with 18F FDG-PET and conventional imaging techniques. Proc Am Soc Clin Oncol 22:651, 2003 (abstr 2618)
14. Bradley JD, Dehdashti F, Mintun MA, et al: Positron emission tomography in limited-stage small-cell lung cancer: A prospective study. J Clin Oncol 22:3248-3254, 2004
15. Blum R, MacManus MP, Rischin D, et al: Impact of positron emission tomography on the management of patients with small-cell lung cancer: Preliminary experience. Am J Clin Oncol 27:164-171, 2004
16. Senan S, De Ruysscher D: Critical review of PET-CT for radiotherapy planning in lung cancer. Crit Rev Oncol Hematol 56:345-351, 2005
17. Fox W, Scadding JG: Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus: Ten-year follow-up. Lancet 2:63-65, 1973
18. Waddell TK, Shepherd FA: Should aggressive surgery ever be part of the management of small cell lung cancer? Thorac Surg Clin 14:271-281, 2004
19. Leo F, Pastorino U: Surgery in small-cell lung carcinoma: Where is the rationale? Semin Surg Oncol 21:176-181, 2003
20. Tsuchiya R, Suzuki K, Ichinose Y, et al: Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 129:977-983, 2005
21. Brock MV, Hooker CM, Syphard JE, et al: Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. J Thorac Cardiovasc Surg 129:64-72, 2005
22. Badzio A, Kurowski K, Karnicka-Mlodkowska H, et al: A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg 26:183-188, 2004
23. Laurie SA, Logan D, Markman BR, et al: Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. Lung Cancer 43:223-240, 2004
24. Faivre-Finn C, Lorigan P, West C, et al: Thoracic radiation therapy for limited-stage small-cell lung cancer: Unanswered questions. Clin Lung Cancer 7:23-29, 2005
25. Pignon JP, Arriagada R, Ihde DC, et al: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327:1618-1624, 1992
26. Warde P, Payne D: Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10:890-895, 1992
27. Carney DN: Lung cancer biology. Semin Radiat Oncol 5:4-10, 1995
28. Roof KS, Fidias P, Lynch TJ, et al: Radiation dose escalation in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 57:701-708, 2003
29. Turrisi AT III, Kim K, Blum R, et al: Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265-271, 1999
30. Movsas B, Moughan J, Komaki R, et al: Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol 21:4553-4559, 2003
31. Schild SE, Bonner JA, Shanahan TG, et al: Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 59:943-951, 2004
32. Videtic GM, Fung K, Tomiak AT, et al: Using treatment interruptions to palliate the toxicity from concurrent chemoradiation for limited small cell lung cancer decreases survival and disease control. Lung Cancer 33:249-258, 2001
33. Choi N, Herndon J, Rosenman J, et al: Long term survival data from CALGB 8837: Radiation dose escalation and concurrent chemotherapy (CT) in limited stage small cell lung cancer (LD-SCLC): Possible radiation dose-survival relationship. Proc Am Soc Clin Oncol 21:298a, 2002 (abstr 1190)
34. Choi NC, Herndon JE II, Rosenman J, et al: Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated- accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 16:3528-3536, 1998
35. Bogart JA, Herndon JE II, Lyss AP, et al: 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: Analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys 59:460-468, 2004
36. Miller AA, Bogart JA, Watson DM, et al: Phase II trial of paclitaxel-topotecan-etoposide (PTE) followed by consolidation chemoradiotherapy for limited stage small cell lung cancer (LS-SCLC): CALGB 30002. J Clin Oncol 23:662s, 2005 (suppl 16; abstr 7170)
37. Langer CJ, Swann S, Werner-Wasik M, et al: Phase I study of irinotecan (Ir) and cisplatin (DDP) in combination with thoracic radiotherapy (RT), either twice daily (45 Gy) or once daily (70 Gy), in patients with limited (Ltd) small cell lung carcinoma (SCLC): Early analysis of RTOG 0241. J Clin Oncol 24:378s, 2006 (suppl 18; abstr 7058)
38. Komaki R, Swann RS, Ettinger DS, et al: Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys 62:342-350, 2005
39. Fowler JF: The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62:679-694, 1989
40. Fried DB, Morris DE, Poole C, et al: Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22:4837-4845, 2004
41. Perry MC, Eaton WL, Propert KJ, et al: Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 316:912-918, 1987
42. Murray N, Coy P, Pater JL, et al: Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11:336-344, 1993
43. Spiro SG, James LE, Rudd RM, et al: Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: A London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol 24:3823-3830, 2006
44. Takada M, Fukuoka M, Kawahara M, et al: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20:3054-3060, 2002
45. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, et al: Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 17:543-552, 2006
46. Huncharek M, McGarry R: A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 9:665-672, 2004
47. Pijls-Johannesma MC, De Ruysscher D, Lambin P, et al: Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 1:CD004700, 2005
48. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al: Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24:1057-1063, 2006
49. Brade AM, Tannock IF: Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: Repopulation as a cause of treatment failure? J Clin Oncol 24:1020-1022, 2006
50. Perry MC: Thoracic radiation therapy in limited stage small-cell lung cancer: Timing is everything, isn't it? J Clin Oncol 24:3815-3816, 2006
51. De Ruysscher D, Bremer RH, Koppe F, et al: Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: A phase II trial. Radiother Oncol 80:307-312, 2006
52. Bremnes RM, Sundstrom S, Vilsvik J, et al: Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer. J Clin Oncol 19:3532-3538, 2001
53. Ettinger DS, Berkey BA, Abrams RA, et al: Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: A Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol 23:4991-4998, 2005
54. Hanna N, Ansari R, Fisher W, et al: Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): A Hoosier Oncology Group (HOG) phase II study. Lung Cancer 35:293-297, 2002
55. Kubota K, Nishiwaki Y, Sugiura T, et al: Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin Cancer Res 11:5534-5538, 2005
56. Levitan N, Dowlati A, Shina D, et al: Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. J Clin Oncol 18:1102-1109, 2000
57. Mitsuoka S, Kudoh S, Takada Y, et al: Phase II study of cisplatin, etoposide and concurrent thoracic radiotherapy (TRT) followed by irinotecan and cisplatin in patients with limited stage small-cell lung cancer (SCLC): Updated results of WJTOG9902. J Clin Oncol 22:627s, 2004 (supp 14; abstr 7044)
58. Sandler A, Declerck L, Wagner H, et al: A phase II study of cisplatin (P) plus etoposide (E) plus paclitaxel (T) (PET) and concurrent radiation therapy for previously untreated limited stage small cell lung cancer (SCLC) (E2596): An Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol 19:491a, 2000 (abstr 1920)
59. Woo IS, Park YS, Kwon SH, et al: A phase II studyofVP-16-fosfamide- cisplatincombinationchemotherapy plus early concurrent thoracic irradiation for previously untreated limited small cell lung cancer. Jpn J Clin Oncol 30:542-546, 2000
60. Glisson B, Scott C, Komaki R, et al: Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: Results of Radiation Therapy Oncology Group Trial 93-12. J Clin Oncol 18:2990-2995, 2000
61. Baas P, Belderbos JS, Senan S, et al: Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: A Dutch multicenter phase II study. Br J Cancer 94:625-630, 2006
62. Noda K, Nishiwaki A, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell-lung cancer. N Engl J Med 346:85-91, 2002
63. Hanna N, Bunn PA Jr, Langer C, et al: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24:2038-2043, 2006
64. Sunpaweravong P, Magree L, Rabinovitch R, et al: A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. Invest New Drugs 24:213-221, 2006
65. Spigel DR, Hainsworth JD, Burris HA, et al: Long-term follow-up of limited stage small cell lung cancer patients treated with carboplatin-based chemotherapy and radiotherapy by the Minnie Pearl Cancer Research Network (MPCRN). J Clin Oncol 22:671s, 2004 (suppl 14; abstr 7222)
66. Iwasaki Y, Nagata K, Nakanishi M, et al: Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer. Chest 128:2268-2273, 2005
67. Ziske C, Gorschluter M, Mey U, et al: Sequential high-dose chemotherapy with autologous stem cell support in patients with limited-stage small cell lung cancer. Anticancer Res 22:3723-3726, 2002
68. Woll PJ, Thatcher N, Lomax L, et al: Use of hematopoietic progenitors in whole blood to support dose-dense chemotherapy: A randomized phase II trial in small-cell lung cancer patients. J Clin Oncol 19:712-719, 2001
69. Takahashi M, Yoshizawa H, Tanaka H, et al: A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer. Bone Marrow Transplant 25:5-11, 2000
70. Gridelli C, Curcio C, Iaffaioli RV, et al: Carboplatin + epirubicin + VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer: A multicenter phase II study. Anticancer Res 21:4179-4183. 2001
71. Elias A, Ibrahim J, Skarin AT, et al: Dose-intensive therapy for limited-stage small-cell lung cancer: Long-term outcome. J Clin Oncol 17:1175, 1999
72. Michael M, Babic B, Khokha R, et al: Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 17:1802-1808, 1999
73. Shepherd FA, Giaccone G, Seymour L, et al: Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 20:4434-4439, 2002
74. Rigas JR, Denham CA, Rinaldi DA, et al: Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI), BAY12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer. Proc Am Soc Clin Oncol 22:628, 2003 (abstr 2525)
75. McClay EF, Bogart J, Herndon JE II, et al: A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). Am J Clin Oncol 28:81-90, 2005
76. Grant SC, Kris MG, Houghton AN, et al: Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 5:1319-1323, 1999
77. Giaccone G, Debruyne C, Felip E, et al: Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 23:6854-6864, 2005
78. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
79. Pujol JL, Breton JL, Gervais R, et al: A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT): An intergroup study FNCLCC Cleo04 - JFCT 00-01. J Clin Oncol 24:378s, 2006 (supp 18; abstr 7057)
80. Raefsky EL, Spigel DR, Greco FA, et al: Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23:633s, 2005 (suppl 15; abstr 7050)
81. Schild SE, Stella PJ, Geyer SM, et al: The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21:3201-3206, 2003
82. Yuen AR, Zou G, Turrisi AT, et al: Similar outcome of elderly patients in Intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 89:1953-1960, 2000
83. Ludbrook JJ, Truong PT, MacNeil MV, et al: Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? A community-based population analysis. Int J Radiat Oncol Biol Phys 55:1321-1330, 2003
84. Uno T, Sumi M, Sawa Y, et al: Process of care and preliminary outcome in limited-stage small-cell lung cancer: Results of the 1995-1997 patterns of care study in Japan. Int J Radiat Oncol Biol Phys 55:626-632, 2003
85. Pottgen C, Eberhardt W, Stuschke M: Prophylactic cranial irradiation in lung cancer. Curr Treat Options Oncol 5:43-50, 2004
86. Auperin A, Arriagada R, Pignon JP, et al: Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission: Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476-484, 1999
87. Tai TH, Yu E, Dickof P, et al: Prophylactic cranial irradiation revisited: Cost-effectiveness and quality of life in small-cell lung cancer. Int J Radiat Oncol Biol Phys 52:68-74, 2002
88. Lee JJ, Bekele BN, Zhou X, et al: Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. J Clin Oncol 24:3597-3603, 2006
89. Videtic GM, Stitt LW, Dar AR, et al: Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 21:1544-1549, 2003
90. Myers JN, O'Neil KM, Walsh TE, et al: The pulmonary status of patients with limited-stage small cell lung cancer 15 years after treatment with chemotherapy and chest irradiation. Chest 128:3261-3268, 2005
91. Tsujino K, Hirota S, Kotani Y, et al: Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation. Int J Radiat Oncol Biol Phys 64:1100-1105, 2006